$PHG

Koninklijke Philips N.V. NY Registry Shares Stock 12‑Month Price Target Cut to $31.15, Implies 22% Upside

Analyst estimates for Koninklijke Philips N.V. NY Registry Shares show the average 12-month price target was cut from $31.34 to $31.15, with a range of $26.64 to $37.57, according to 18 analysts. Based on the Jul. 28 close, the target suggests about 22% upside. The consensus rating remains “Buy” (10 Buys, 11 Holds, 0 Sells) from 21 analysts.

Original reporting
Published Jul 29, 2026, 1:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 2:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Koninklijke Philips N.V. NY Registry Shares Stock 12‑Month Price Target Cut to $31.15, Implies 22% Upside — source image
Decision brief

The 30-second read

$PHGNeutralLow
01

Why it matters

A reduction in the average price target to $31.15 suggests some analysts trimmed expectations, but the unchanged “Buy” consensus (10 Buys, 11 Holds, 0 Sells) indicates no broad negative re-rating.

02

Market read

Traders may treat this as a small sentiment update rather than a catalyst, given no new operational or regulatory information.

03

What to watch

The article lacks the underlying analyst rationale (earnings revisions, margin assumptions, or demand outlook), so traders should not over-interpret the PT change as a fundamental deterioration.

Relevance 4/10Novelty 4/10Timing: today’s analyst price-target update (published 2026-07-29)

Background

The piece summarizes FactSet-based analyst consensus for Koninklijke Philips N.V. NY Registry Shares, focusing on the average price target and rating distribution.

Company-level read

Ticker impact

$PHGNeutralMedium confidence
Context

Philips’ average analyst price target fell from $31.34 to $31.15, with a consensus “Buy” rating unchanged across 21 analysts.

Expected impact

Near-term bias slightly negative versus prior target, but likely muted given “Buy” consensus and no new operating catalyst.

Evidence & confidence

The article provides only analyst estimate revisions (PT range and consensus mix) and no new company-specific fundamentals, guidance, or events.

Market effects

Limited read-through to healthcare/medtech analyst sentiment since this is a single-company PT adjustment with no thesis details.

None indicated; the update is analyst-driven rather than macro or regional policy.

Low, as it does not cite new global demand, regulation, or competitive developments.

Counterpoint

A PT cut can reflect valuation recalibration rather than deteriorating fundamentals, especially with “Buy” consensus and zero “Sell” ratings.

Key entities

  • Koninklijke Philips N.V. NY Registry Shares

    Subject of the article; analyst average price target cut to $31.15 with consensus “Buy” maintained.

Related articles

$PHGMed

Philips Gets a Tariff Refund, Not a Clean Bill of Health

Philips reported Q2 sales of €4.4B (up 4% comparable) and an adjusted EBITA margin of 16.4%. The company said a €186M US tariff refund drove most of the margin improvement, while underlying margin fell. Orders were down 1% comparable, with some North America Connected Care contracts delayed. Full-year sales guidance was unchanged; margin and free cash flow guidance were raised.

$PHGMed

Philips Stock Falls 9% as Weak Orders Overshadow Outlook

Philips (PHG) shares fell about 9% in European trading after the company reported weaker-than-expected orders and warned that conditions in China are getting harder. Philips said comparable order intake fell 1% mainly due to delays in closing large U.S. contracts. It kept an improved full-year profitability outlook but expects third-quarter adjusted EBITDA margin below last year.

$PHGMedAI 8/10

Philips beats Q2 profit estimates due to tariff refunds

Philips reported Q2 adjusted EBITA margin of 16.4%, above analysts’ 12.1% forecast, helped by US tariff refunds. The company said it largely completed the refund process during the quarter. Philips raised its 2026 outlook to an adjusted EBITA margin of 13.5%-14% (from 12.5%-13%) and forecast free cash flow of €1.5-1.7 billion. Sales rose 4% to €4.4 billion.